Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Trattamento del dolore cervicogenico cronico alla testa e al collo (CGH)

30 settembre 2026 aggiornato da: Richard Hallgren, Michigan State University

Trattare il dolore cervicale cronico alla testa e al collo con la manipolazione osteopatica e la terapia fisica

The primary aim is to test the combined effectiveness of OMT and targeted head exercise (THE) to achieve a significant decrease in headache measures of frequency, intensity, and duration in a Treatment group when compared to a Control group whose members receive only standard medical care. A parallel, 2-arm, longitudinal, randomized controlled trial (RCT) will focus upon female patients (18 to 75 years of age) who have been diagnosed with chronic cervicogenic headache (CeH) based upon a differential diagnosis that includes classification according to the International Headache Society Classification IHSD 3rd Edition, reproduction of referred headache resulting from manual pressure over the upper cervical regions, and objective MRI findings. It is estimated that a sample size of 30 will provide sufficient statistical power (79%) to detect an intervention effect that corresponds to a clinically meaningful recovery (60%).

CeH is classified as a secondary headache disorder because the headache pain is a consequence of injury to, or disease of, the bony and/or soft tissues of the upper cervical spine. It has been reported that some patients diagnosed with CeH demonstrate atrophy and/or fatty infiltration (FI) of the RCPm muscles on MRI. FI and/or a reduction in the cross-sectional area (CSA) of active muscle would not be expected to be the direct cause of chronic headache, but either or both could prevent muscles from generating normal physiologic levels of force. It has been shown that there is a functional connection between the pain sensitive dura mater and RCPm muscles and it is known that mechanical stretching of the dura mater results in referred headache.

While FI and/or a reduction in the CSA of active muscle would not be expected to be the direct cause of chronic headache, it is known that muscle pathology will result in functional deficits. It is proposed that pathology in RCPm muscles will compromise the normal functional relationship between the RCPm and the dura mater and result in referred head and neck pain. It is predicted that at the end of the study, the Treatment group will show a significant decrease in headache measures that will be accompanied by a significant increase in CSA and a significant decrease in FI on MRI, and restoration of a normal head posture that will not be seen in the Control group.

The proposed study is unique in that we are proposing both a mechanism and a source for some instances of CeH. By testing the effectiveness of specific interventions to address a specific pathology within a specific headache population, and by restricting the study cohort to female subjects presenting with CeH, this study will increase the ability to detect a significant change in the outcomes by increasing the power of the statistical analysis.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

CeH preferentially effects female headache patients (Racicki et al., 2013). CeH is classified as a secondary headache disorder because the source of the pain is thought to be a consequence of injury to, or disease of, the bony and/or soft tissues of the upper cervical spine (Kristoffersen et al., 2017). Clinical management of CeH is challenging for the physician because a pathology that would account for the pain is usually unknown.

The primary diagnostic criteria that physicians use to diagnose CeH is based upon classification according to the International Headache Society Classification IHSD 3rd Edition (HIS, 2013). CeH is characterized by unilateral head or face pain without side shift that is of moderate to severe intensity of varying duration (Antonaci et al., 2001). CeH may occasionally be bilateral, throbbing, and accompanied by nausea, vomiting, phonophobia, photophobia, and dizziness when chronic tension-type headache and chronic migraine attacks are superimposed (Biondi, 2005). If the source of CeH originates in the upper cervical spine, osteopathic physicians can use head and neck movements and pressure applied to the suboccipital and lower cervical regions (Anarte-Lazo et al., 2021) to provoke referred headache. These diagnostic techniques, along with restricted active and passive range of motion (ROM) of the head and neck (Ogince et al., 2007), provide additional credibility that the diagnosis of CeH is valid (Avijgan et al., 2020) and helps ensure that the efficacy of our treatment protocol is not weakened by applying it to subjects with a different type of headache, such as migraine, that would not be expected to respond to a treatment protocol designed for CeH patients (Bogduk N, 2014).

The largest study of conservative therapy for cervicogenic headache (Jull et al., 2002) reported that manual therapy alone was not more effective than exercises alone. The study reported that headache frequency was reduced by 50% at a 7-week follow up, but figures for reduction in pain intensity were not reported. They reported that combining manipulation and exercise was not significantly superior to either therapy alone. Hidalgo et al., (2017) have reported that combining the 2 therapies is better than either manipulation or exercise alone. The weakness of Jull et al's. (2002) study was that their treatment protocol was applied to subjects who would not have had a common etiology for their headache pain. CeH is defined by injury to, or disease of, the bony and/or soft tissues of the upper cervical spine (Bogduk N, 2014). MRI is the gold standard for diagnostic assessment of structures of the upper cervical spine (Sun et al., 2020), but Jull et, al.'s (2002) study did not include an MRI assessment of the upper cervical spine in their inclusion/exclusion criteria. The outcome of their study reported that their treatment protocol showed a positive effect, but not one that rose to a significant level. I suggest this was due to mixing headache types (CM and CeH) that have different etiologies and expecting a single treatment protocol to address both pathologies.

Since CeH results from injury to, or disease of, the bony and/or soft tissues of the upper cervical spine, it is only reasonable to exclude those patients who do not present with pathology on MRI in the upper cervical spine (Sun et al.,2020). Our study is unique in that we will test the effectiveness of specific interventions that address a specific pathology within a specific headache population. By actively restricting the study cohort to a specific headache population, we will increase our ability to detect a significant change in the outcomes of treatment by increasing the power of the statistical analysis.

This study is unique in that it proposes to investigate a mechanism responsible for referred pain in some instances of chronic CeH. The effectiveness of specific interventions to address a specific pathology within a specific headache population will be tested. It is proposed that pathology in RCPm muscles has been undervalued, primarily because of their small size and a misunderstanding of their functional significance. By actively restricting the study cohort to a specific headache population, the power of the statistical analysis will be increased. It is hypothesized that the combined use of OMT and THE will decrease headache measures of frequency, intensity and duration, will increase the CSA and reduce the percentage of fatty infiltration (FI) of RCPm muscles on MRI, and will reduce forward head posture (FHP) in female patients diagnosed with CeH.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Michigan
      • East Lansing, Michigan, Stati Uniti, 48824
        • Michigan State University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria: Females diagnosed with chronic cervicogenic headache.

Exclusion Criteria:

  • Have you been involved in a rear-end motor vehicle accident within the past 3 years?
  • Have you had spinal surgery performed on your neck?
  • Do you have a pinched nerve in the neck that produces pain radiating down your arm.
  • Have you been diagnosed with diseases such as rheumatoid arthritis, lupus, or ankylosing spondylitis.
  • Do you have ongoing central nervous system pathology such as hemiparesis, cervical radiculopathy, spondylolisthesis grade III or IV, central nervous system causes of balance & coordination deficits, orthostatic hypotension, vestibular disorders, pregnancy, recent spinal fractures, moderate to severe traumatic brain injury.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment

All subjects in the Treatment group will receive OMT a minimum 4 times and a maximum of 8 times at the physician's (JJR) discretion (Jull et al., 2002). All subjects in the Treatment group will be taught the THE. This voluntary head retraction/protrusion exercise protocol engages the RCPm muscles in eccentric and isometric contractions that should strengthen the muscles and thereby increase CSA.

At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.

The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head.

Nessun intervento: Control

All subjects assigned to the Control group will be allowed to continue to receive conservative care. It is understood that any care that they receive will be prescribed on an individual basis. A participant could therefore receive any combination of medical, physio therapeutic and psychological care. It would also be expected that some form of pain management will be a priority for participants with moderate to severe symptoms. Subjects assigned to the Control group will not receive OMT and will not be taught the THE protocol.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cervicogenic Headache
Lasso di tempo: 18 months

Reduction of headache frequency

18 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 settembre 2022

Completamento primario (Effettivo)

7 aprile 2025

Completamento dello studio (Effettivo)

1 giugno 2026

Date di iscrizione allo studio

Primo inviato

5 novembre 2022

Primo inviato che soddisfa i criteri di controllo qualità

14 novembre 2022

Primo Inserito (Effettivo)

15 novembre 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 016507-00001

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .